Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | TP53 | P04637 | 2/20 | 0.75 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | CA4 | P22748 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.58 |
| ▸ | NT5E | P21589 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.54 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6663776 | 0.90 | ADORA3 (0.69) | ADORA3LMNATP53CA1CA2 | |
| SCHEMBL4451640 | 0.89 | ADORA3 (1.00) | ADORA3CA1CA2CA4CA9 | |
| SCHEMBL16160996 | 0.89 | ADORA3 (0.74) | ADORA3LMNATP53CA1CA2 | |
| SCHEMBL4451649 | 0.89 | ADORA3 (1.00) | ADORA3CA1CA2CA4CA9 | |
| SCHEMBL7531797 | 0.88 | ADORA3 (0.66) | ADORA3LMNATP53CA1CA2 | |
| SCHEMBL8820007 | 0.86 | ADORA3 (0.83) | ADORA3ADORA2AADORA1ADORA2BNT5E | |
| SCHEMBL8820000 | 0.86 | ADORA3 (0.83) | ADORA3ADORA2AADORA1ADORA2BNT5E | |
| SCHEMBL23982228 | 0.86 | LMNA (1.00) | ADORA3LMNATP53ADORA2AADORA1 | |
| SCHEMBL638999 | 0.86 | LMNA (1.00) | ADORA3LMNATP53ADORA2AADORA1 | |
| SCHEMBL10607959 | 0.86 | LMNA (1.00) | ADORA3LMNATP53ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654884-B2 | Purine derivatives as CD73 inhibitors for the treatment of cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-05-19 | — | — | US | disclosed |
| US-20170044203-A1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654884-B2 | Purine derivatives as CD73 inhibitors for the treatment of cancer | ENTPD5, NT5E, ENTPD1 | ADORA3 33/4885LMNA 2227/4885TP53 290/4885 |
| US-20170044203-A1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | ENTPD5, ENTPD1, NT5E | ADORA3 28/4885LMNA 2579/4885TP53 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.